Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC prevails over Medlab

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission's motion for summary judgment is granted in its action against the makers of weight-loss pills alleging false and unsubstantiated advertising claims. The April 21 order issued by the U.S. District Court for the Northern District of California says corporate defendants Medlab, Pinnacle Holdings, Metabolic Research Associates and their principal Scott Holmes are liable for $2.7 million, representing gross sales of a weight-loss product sold as Zyladex, Questral AC and Rapid Loss. The newspaper ads in question claimed a user could "lose up to 15 pounds a week with the amazing formula that forces your body to release fat" and said "not even total starvation can slim you down and firm you up" as quickly as Zyladex Plus can, the ruling said. The court found that small-type disclaimers stating results may vary do not counter misleading weight-loss claims. FTC filed the suit in February 2008 to bar the defendants from further violations (1"The Tan Sheet" Feb. 18, 2008, In Brief)

The Federal Trade Commission's motion for summary judgment is granted in its action against the makers of weight-loss pills alleging false and unsubstantiated advertising claims. The April 21 order issued by the U.S. District Court for the Northern District of California says corporate defendants Medlab, Pinnacle Holdings, Metabolic Research Associates and their principal Scott Holmes are liable for $2.7 million, representing gross sales of a weight-loss product sold as Zyladex , Questral AC and Rapid Loss . The newspaper ads in question claimed a user could "lose up to 15 pounds a week with the amazing formula that forces your body to release fat" and said "not even total starvation can slim you down and firm you up" as quickly as Zyladex Plus can, the ruling said. The court found that small-type disclaimers stating results may vary do not counter misleading weight-loss claims. FTC filed the suit in February 2008 to bar the defendants from further violations (1 'The Tan Sheet' Feb. 18, 2008, In Brief).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel